Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 181-200 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 181 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: The reviewed sources only indicates Earth Eye Co is a Chinese private company associated with the TEE-01B surveillance satellite used for imaging and surveillance. This suggests some asset relevance in Earth observation, but there is no direct business traction or positive catalyst evidence available. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 182 | Exquadrum, Inc. lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources rationale describes Exquadrum as a rocket-maker acquired by Mach Industries, which at least indicates strategic relevance to launch/propulsion capabilities if the acquisition meaningfully advances commercialization (: no provided in reviewed sources). Why now: No retained evidence establishes current milestone timing or post-acquisition integration progress, so there is no strong why-now supported in these reviewed sources. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Acquisition context is weaker than direct operating evidence. |
| 183 | Fergani Space lowweak | Opp 2 Risk 2 | Thesis: Reviewed evidence rationale suggests Fergani Space launched a fifth test satellite into LEO with communications and navigation capabilities, which could indicate technical progress if still current, but no direct post-recent evidence window evidence are available to support a durable 1 year+ opportunity thesis. Why now: There is no credible 'why now' catalyst in the reviewed sources because articles after recent evidence window and evidence after recent evidence window are both zero for this company. The only cited support is older or excluded from the active evidence set: article, referenced in the membership rationale, was outside the kept recent evidence window according to the company coverage report. Caveats: No evidence were available after recent evidence filtering. No representative articles or additional_company_articles were provided. Membership rationale is weaker than direct event/fact evidence. |
| 184 | Filtronic PLC lowweak | Opp 2 Risk 1 | Thesis: Older reviewed sources context says Filtronic is in a space/satellite communications context and has a SpaceX deal via article, which could be positive if current, but there is no retained in-window direct positive evidence with to justify a stronger ranking. Why now: There is no evidenced near-term or durable why-now catalyst inside the retained 90-day evidence window. Caveats: Reviewed evidence references but provides no representative article. Potentially positive older context may be stale or superseded; recency cannot be validated. No retained evidence after recent evidence window. |
| 185 | GalaxEye Space lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources membership rationale describes GalaxEye as launching Mission Drishti, an OptoSAR satellite with defense and disaster-response use cases, which is strategically interesting, but no within the recent evidence window direct evidence is available to support a stronger ranked opportunity. Why now: There is no within the recent evidence window evidence available in these reviewed sources for GalaxEye Space; timing and maturity of current milestones cannot be confirmed from reviewed sources evidence. Caveats: Membership rationale cites article IDs and, but their article content is not provided here for citation. Evidence recent evidence review shows 0 kept rows. This entity may overlap with GalaxEye Space Solutions Private Ltd, but the output contract requires scoring both separately. |
| 186 | GALVANY lowweak | Opp 2 Risk 2 | Thesis: The membership rationale says GALVANY raised a €10M seed in a European tech funding roundup, which is at least a financing signal that could support future execution. However, the reviewed sources explicitly says funding alone is insufficient without a clear space linkage, and there are no available direct evidence after recent evidence window. Why now: The only possible timing angle is the referenced seed raise in the membership rationale, but no -backed available evidence remains after the recent evidence filter, so recency and impact cannot be validated for scoring. Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Funding context does not prove target-cohort fit. |
| 187 | GEOST lowweak | Opp 2 Risk 2 | Thesis: GEOST may retain strategic relevance through its cited prototype development role in space domain awareness and the note that it is now Rocket Lab Optical Systems after acquisition, but the reviewed sources provide no retained recent evidence window-window evidence to support a current standalone upside thesis. Why now: There is no retained within the recent evidence window evidence. Any thesis would rely on older context referenced in the membership rationale, which is insufficient for a stronger rank. Caveats: Reviewed evidence references acquired-business context rather than current standalone operations. No representative articles or retained evidence are included. Low scores reflect missing timely evidence, not a directional call on the business. |
| 188 | GHGSat lowweak | Opp 2 Risk 2 | Thesis: GHGSat likely has strategic relevance as a commercial greenhouse-gas monitoring satellite company, but the reviewed sources includes no available dated evidence to support a stronger opportunity ranking. Why now: The reviewed sources offers no recent evidence window-supported event timing for a why-now view. Caveats: The membership rationale says GHGSat is the world's leading commercial greenhouse gas monitoring satellite company, but the supporting article content is not available here for ranking use. Absence of negative evidence is not positive evidence. |
| 189 | Globalstar lowweak | Opp 2 Risk 2 | Thesis: Globalstar is described in membership rationale as a satellite communications and direct-to-device company, but the reviewed sources includes no available within the recent evidence window positive evidence to support a stronger ranked opportunity view. Why now: No within the recent evidence window evidence were available for Globalstar in these reviewed sources, so there is no current catalyst basis to elevate either opportunity or risk. Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. Membership rationale cites article IDs, and: but those article contents are not provided here for direct factual citation. Public company status does not improve ranking without directional evidence. |
| 190 | Guoxing Aerospace Technology lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources rationale says Tencent partners with Guoxing Aerospace for Star Computing AI cloud in an article about space-based AI computing, which could imply exposure to a longer-horizon emerging segment if substantiated by direct evidence (: no provided in reviewed sources). Why now: Space-based AI computing could be strategically relevant over 1 year+, but the reviewed sources provide no retained dated evidence to confirm partnership scope, timing, or commercial milestones. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Partnership mention alone is insufficient to prove durable company impact. |
| 191 | HawkEye 360, Inc. lowweak | Opp 2 Risk 1 | Thesis: The reviewed sources membership rationale says HawkEye 360 provides RF intelligence/data services and has government-linked business, which could support a durable demand thesis, but no within the recent evidence window evidence or article summaries are available to justify a stronger score. Why now: There is no available post-recent evidence window evidence in the reviewed sources to establish a current catalyst or changed business state. Caveats: No evidence available after recent evidence window. Cannot rely on membership rationale alone for direction. |
| 192 | HawkEye 360, Inc. lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources indicates HawkEye 360 is a space intelligence company with a satellite constellation and government-contract exposure, which could be attractive over a multi-year horizon if contract flow and constellation utilization continue. Why now: The only retained dated item is an April 5, 2026 supporting article context entry stating HawkEye 360 is a data analytics company developing space-based radio frequency mapping and a satellite constellation startup: That is too weak to establish a strong current catalyst. Caveats: Only weak supporting article context is retained after recent evidence window; no direct event/fact evidence is available. Phase2 rationale mentions 30+ satellites and government contracts, but the reviewed sources does not provide those source articles in detail here. |
| 193 | Innoseis lowweak | Opp 2 Risk 1 | Thesis: Innoseis has the strongest limited positive context in this screen because the membership rationale says it raised €6M and has applications in space exploration, with technology selected for future Moon measurements, which could support a long-horizon opportunity if substantiated by direct evidence (: unavailable in reviewed sources). However, the reviewed sources have no direct positive evidence within the recent evidence window, so the thesis remains low confidence. Why now: Potentially relevant because the article context references funding and lunar-measurement selection, but the reviewed sources provide no dated evidence or, so recency and sequence cannot be verified beyond the membership rationale tied to Caveats: No current evidence is provided for cited Zero evidence available after recent evidence window despite the membership rationale. Funding and technology-selection references are article-context level only here. |
| 194 | Intelsat lowweak | Opp 2 Risk 1 | Thesis: The only positive indication in the reviewed sources are membership rationale stating Intelsat participated with Viasat in a Space Force mini-GEO satellite award, which could support a long-horizon government satcom opportunity if current and material, but no direct evidence or article summaries are available after the 90-day recent evidence window. Why now: Why now is weak because coverage data shows 0 article IDs after recent evidence window and 0 evidence available after recent evidence window, so timing and durability cannot be validated from these reviewed sources. Caveats: Membership rationale cites article IDs: and: but the reviewed sources provide no or summaries for them. Evidence recent evidence review shows kept_rows 0 and undated_rows_kept 0, so there is no usable direct evidence inside the ranking window. Cannot treat cohort membership as thesis attractiveness. |
| 195 | Intelsat General lowweak | Opp 2 Risk 2 | Thesis: Reviewed evidence membership rationale says Intelsat General was tied to a Space Force PTS-G satellite contract, which could support long-horizon defense-space opportunity, but no post-recent evidence window evidence or article summaries were available for scoring. Why now: Why-now support is weak because coverage data shows zero article/evidence after the 90-day recent evidence window, so recency for the cited contract context cannot be validated from available evidence. Caveats: Phase2 membership rationale references: but no representative article or evidence row is available after recent evidence window for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Scored low due to evidence absence, not due to negative business evidence. |
| 196 | iQPS lowweak | Opp 2 Risk 1 | Thesis: Membership rationale says Rocket Lab secured a multi-launch agreement with iQPS for SAR satellites, which suggests iQPS may have meaningful constellation deployment activity over a 1 year+ horizon if current. Why now: Why now is limited because the support is only referenced through membership rationale citing articles and, but the reviewed sources provide no or retained evidence after recent evidence window. Caveats: No or article summaries are provided for cited support articles and. Coverage data shows zero retained evidence after recent evidence window. Potentially interesting launch-agreement signal cannot be scored highly without direct reviewed sources evidence. |
| 197 | Jacobs lowweak | Opp 2 Risk 2 | Thesis: Jacobs has evidence of a large Space Force Range Contract award worth up to $4 billion over 10 years, which would ordinarily support a positive thesis, but the relevant articles are dated June 3, 2025 and are outside the reviewed sources' 90-day recent evidence window, so current opportunity support is weak in these reviewed sources. Why now: Why now is weak because the contract evidence is older. The reviewed sources cites Space Force and SpaceNews articles dated June 3, 2025, which are outside the 90-day evidence window Caveats: Contract evidence exists but falls outside the selected 90-day recent evidence window. No direct positive or negative evidence remain after recent evidence filtering. |
| 198 | Jio Platforms lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources rationale says Jio Platforms is the vehicle for Reliance's planned multi-billion-dollar LEO satellite communications entry and planned network to compete with Starlink and Kuiper, which suggests long-horizon optionality if execution proceeds, but no underlying article evidence is provided in these reviewed sources output. Why now: Why now is not well supported in the served evidence because no representative articles or direct evidence are available after recent evidence window despite the membership rationale referencing article IDs, and Caveats: No representative articles or direct evidence are included in the reviewed sources output. Membership rationale is not a substitute for direct thesis evidence. Recency and event sequence cannot be judged from the missing article details. |
| 199 | Karman Holdings Inc. lowweak | Opp 2 Risk 1 | Thesis: Karman Holdings has modest contextual upside because the membership rationale says the reviewed sources placed it in broad space/defense and supply-chain articles and provided revenue facts, which may indicate operating scale or relevance to a durable strategic cycle, unavailable in reviewed sources). But there is no available direct positive evidence after recent evidence window, so this does not support more than a low opportunity score. Why now: Why now is weak because there are no retained evidence after the 90-day cutoff date of March 29, 2026, despite multiple older considered articles. Caveats: No current evidence is provided for and. Revenue facts are referenced only in the membership rationale, not available as direct evidence. Broad supply-chain context is weaker than company-specific contract or product evidence. |
| 200 | Korea Aerospace Industries (KAI) lowweak | Opp 2 Risk 2 | Thesis: Limited opportunity based only on the reviewed sources membership rationale that identifies CAS500-2 as an Earth observation satellite for KAI, indicating confirmed participation in a qualifying satellite activity but not providing a new catalyst, contract, backlog, or financial inflection. Why now: Why now is weak because the reviewed sources say one article supported membership, article ID: but no, timing detail, or direct evidence were available after recent evidence window. Caveats: No direct evidence or article summaries were available after recent evidence window. Membership support references article ID: without a in the reviewed sources. |
Risk view
Showing rows 61-80 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 61 | Xoople mediummedium | Opp 6 Risk 4 | Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise. Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize. Evidence
Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available. |
| 62 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 63 | Aavuus mediummedium | Opp 5 Risk 3 | Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon. Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026 Evidence
Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation. |
| 64 | Applied Atomics lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload. Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak. Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources. |
| 65 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 66 | Astroscale lowweak | Opp 5 Risk 3 | Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale. Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible. Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated. |
| 67 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
| 68 | CAS Space lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence. Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst. Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources. |
| 69 | CesiumAstro lowweak | Opp 5 Risk 3 | Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking Evidence
Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source. |
| 70 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 71 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 72 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 73 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 74 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 75 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 76 | EON Space Labs lowweak | Opp 1 Risk 3 | Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields. Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here. Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone. |
| 77 | Eycore mediumweak | Opp 5 Risk 3 | Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders. Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage. Evidence
Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided. |
| 78 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 79 | Goonhilly Earth Station Ltd lowweak | Opp 3 Risk 3 | Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked. Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated. Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously. |
| 80 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |